Business Wire

BACARDI-LIMITED

13.2.2020 14:17:09 CET | Business Wire | Press release

Share
Bacardi Limited Paves the Way For A Good Spirited Future

Family-owned Bacardi Limited has been doing the right thing for its people, its community and the planet more than 158 years. Today, the company released its fiscal year 2019 Good Spirited Corporate Responsibility (CR) Report to provide open and transparent communications in how it’s championing commitments within its CR pillars of marketplace , people , environment , responsible sourcing , and philanthropy and community investment . From responsible drinking efforts, to driving a positive and diverse culture, to hurricane disaster relief and reducing the impact on natural resources, the Good Spirited Corporate Responsibility Report outlines progress in fiscal year 2019, alongside commitments for the future. This marks the 12th annual CR report issued by privately-held Bacardi Limited.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200213005465/en/

“Being family-owned for seven generations allows us to stay true to our values of being fearless to innovate, behaving like family to each other and our communities, and exhibiting founders mentality in always doing the right thing -- particularly towards making the world a more sustainable, safe and transparent place,” says Rick Wilson, Senior Vice President of Corporate Responsibility at Bacardi. “It’s extremely gratifying to see us achieve key milestones, in some cases ahead of time, and to continuously pursue new goals and set higher standards for the future.”

The report outlines the overall marketplace for spirits and addresses the responsibility Bacardi has in promoting responsible drinking practices and targeting our marketing only to legal age drinkers. With the evolution of digital marketing, the company has doubled down efforts to enforce safeguards to limit minors from seeing alcohol marketing online. Bacardi has achieved 79% compliance in establishing these safeguards with an aim to be 100% compliant by 2020. Bacardi has also been an early mover in the space of nutrition transparency, with the launch of a Bacardi nutrition website in key markets giving consumers more information about what they’re drinking including calories and allergens.

The vibrant, warm and entrepreneurial culture at Bacardi is reflected in the exceptional employee engagement with the global internal survey showing 89% of employees saying they are “proud to work for the company.” External perception of the company is also positive as Bacardi Limited was named among the most reputable companies in the world as part of the annual Global RepTrak® 100 list compiled by the Reputation Institute (RI) and published in Forbes. Ranked at #87, Bacardi Limited climbed two spots and has made the annual global list seven consecutive times.

Bacardi believes in the inherent value that can be created when you bring together a diverse and inclusive community and workplace. Helping female talent at Bacardi, and within our community, is among the many causes championed by the company through its Global Reflections program. The company has made considerable headway with women making up 44% of North America and 40% of Europe – which represent the two largest regions of the business. In addition, 37% of the leadership positions in the company were held by women in fiscal year 2019 and the company continues to work towards narrowing the gender gap.

Bacardi continues to push the boundaries with aspirations to be the world’s most environmentally responsible global spirits company. Finding a second life for all waste is a priority and the company’s production facilities have achieved 99.6% of waste diversion. Despite increases in production, the company has been able to reduce greenhouse gas emissions from operations by 20% and cut water consumption by almost 10% through efficiencies in assets utilization. It is also committed to the long-term sustainability and responsible sourcing of sugarcane, agave, wheat, botanicals, and other natural resources needed to craft its world-class premium products. Already 98.4% of the sugarcane-derived products used in BACARDÍ® rums are sourced from suppliers certified by Bonsucro, with the goal of reaching 100% by the end of fiscal year 2020, three years ahead of initial targets. The company also achieved ECOCERT certification for 50% of botanicals for BOMBAY SAPPHIRE® gin with a goal to certify 100% of the botanicals in the coming year. With an eye for the future and always pushing to do greater good, Bacardi has defined a long-term plan to reduce greenhouse gas emissions by 20% and water consumption by 25% by fiscal year 2024.

Going beyond the company to care for the community is part of the DNA at Bacardi since its inception in 1862. Bacardi, together with Mercy Corp, continues to support the long-term recovery efforts in Puerto Rico, where BACARDÍ rum is produced, after devastation from Hurricanes Maria and Irma in 2017, providing habitat rehabilitation, financial grants, business training, and marketing support to 243 businesses on the island.

To read more about Corporate Responsibility within Bacardi, check out the complete FY19 Corporate Responsibility Report, which encompasses April 1, 2018 – March 31, 2019, online https://www.bacardilimited.com/corporate-responsibility/ .

About Bacardi Limited

Bacardi Limited, the largest privately held spirits company in the world, produces and markets internationally recognized spirits and wines. The Bacardi brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, and ERISTOFF® vodka.

Founded more than 158 years ago, in Santiago de Cuba on February 4, 1862, family-owned Bacardi currently employs more than 7,000, operates more than 20 production facilities, including bottling, distilling and manufacturing sites in 11 countries, and sells its brands in more than 170 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit www.bacardilimited.com or follow us on Instagram , LinkedIn and Twitter .

Enjoy Responsibly.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye